Akili Interactive Labs

Market position

Akili was one of the earliest and most visible prescription digital therapeutics companies, holding one of the first FDA clearances in the category and setting reference points for clinical validation in the field. Despite this position it did not convert regulatory success into a sustainable commercial business, and its take-private sale followed the bankruptcy of Pear Therapeutics and the asset sale of Better Therapeutics to Click Therapeutics, part of a broader contraction among digital health companies that expanded during the COVID-19 period.

Akili positioned its products as clinically validated medicine rather than wellness software, citing prospective randomized controlled trials and FDA clearance of EndeavorRx as the first and only prescription treatment delivered through a video game. Its patented Selective Stimulus Management Engine combines sensory stimuli with simultaneous motor challenges and adaptive algorithms that personalize the treatment to each patient, and the underlying platform captured gameplay data at high frequency for remote monitoring and analysis. The company drew engineering talent from gaming, pharmaceutical, and entertainment backgrounds, using industry-standard game development tools.

Technology

Akili's products are built on the Akili Selective Stimulus Management Engine (SSME), a proprietary and patented technology designed to target key attentional control systems in the brain. Delivered through an action video game experience, SSME presents specific sensory stimuli alongside simultaneous motor challenges to activate neural systems involved in attention function, while adaptive algorithms personalize the treatment to each patient. The approach derives from research on interference processing and the NeuroRacer prototype developed by co-founder Adam Gazzaley. Early versions, such as Project: Evo, ran on iPad and iPhone and required the player to steer a character by tilting the device while tapping in response to specified on-screen targets; a back end harvested gameplay data 30 times per second for remote monitoring and analysis. Engineering used open-source software and industry-standard game development tools.

Go-to-market

Initially a prescription model in which EndeavorRx reached families through healthcare professionals, supported by a commercial organization using Salesforce and Veeva CRM systems. Following limited commercial traction, Akili added a direct-to-consumer channel in the form of EndeavorOTC for adults with ADHD, which produced some sales growth, and then moved toward licensing its technology to a pharmaceutical partner.

Children with ADHD and their families, reached via prescribing healthcare professionals; later adults with ADHD purchasing directly; and, more broadly, people affected by acute and chronic cognitive impairments, including those with COVID-related brain fog. Pharmaceutical partners such as Pfizer and Shionogi served as research and licensing counterparties.

Geography

Headquartered in Boston, Massachusetts, with a second office in Larkspur, California, and a hybrid on-site/remote working model. The company stated intentions to expand its global footprint within ADHD and other indications, and licensed its technology to Japan-based Shionogi.

History

Akili was founded in December 2011 and incubated by PureTech in Boston, launching Project: Evo as an iPad game intended to both detect and treat cognitive impairment. By 2014 it had roughly 5.5 employees and about $7 million in funding, and was running trials in Alzheimer's risk detection with Pfizer as well as studies in ADHD, autism, and depression. EndeavorRx received FDA clearance in June 2020, and in May 2021 the company announced $160 million in combined financing, bringing total equity funding to $230 million. Akili went public via a SPAC merger in 2022 that raised roughly $163 million and briefly valued it above $1 billion. Commercial uptake fell short; the company added direct-to-consumer sales, cut jobs, paid down debt, announced a strategic review in April 2024, and agreed in late May 2024 to be acquired by Virtual Therapeutics in a take-private merger worth about $34 million.

Risks & controversies

Akili's prescription-first commercial strategy failed to gain traction, and successive pivots including direct-to-consumer sales did not produce a sustainable business model. Revenues remained minimal relative to operating losses, the share price fell from a SPAC valuation of roughly $1 billion to a market capitalization of about $33 million, and the company implemented job cuts and other cost reductions before agreeing to a take-private sale at approximately $0.43 per share.